Biosimilar switching – current state of knowledge
Open Access
- 31 August 2018
- journal article
- review article
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 56 (4) , 234-242
Abstract
Evidence from over 10 years of clinical experience demonstrates that biosimilar medicines approved in the European Union can be used for all their registered indications as safely as their originators and with no negative impact on therapeutic efficacy. The debate on the use of biosimilars in rheumatology focuses specifically on the safety of switching between biosimilars and reference products. Studies conducted to date, including randomised double-blind and open-label extension trials, have not demonstrated any significant differences in therapeutic efficacy or safety between patients switched from one medicine to another and those who were continued on a single medicine. According to the latest recommendations for the use of biosimilars in rheumatic diseases, developed by an international task force in 2017, there is no clinical evidence that a single switch from an originator to a biosimilar medicine is associated with any significant risk for patient safety or reduction in therapeutic efficacy.Keywords
This publication has 24 references indexed in Scilit:
- Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4Annals of the Rheumatic Diseases, 2017
- Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY studyJournal of the European Academy of Dermatology and Venereology, 2017
- A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnnals of the Rheumatic Diseases, 2017
- Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilarsExpert Opinion on Biological Therapy, 2017
- Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy dataDrug Design, Development and Therapy, 2017
- Molecular “Sameness” Is the Key Guiding Principle for Extrapolation to Multiple IndicationsClinical Pharmacology & Therapeutics, 2017
- Interchangeability of Biosimilars: A European PerspectiveBioDrugs, 2017
- The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasisBritish Journal of Dermatology, 2016
- Biosimilars in rheumatology: current perspectives and lessons learntNature Reviews Rheumatology, 2015
- The safety of switching between therapeutic proteinsExpert Opinion on Biological Therapy, 2012